世界の良性前立腺肥大症(BPH)治療市場:産業分析・成長予測(~2030)

◆英語タイトル:Benign Prostatic Hyperplasia Treatment Market Research Report: By Type (Drug Treatment, Surgical Treatment), End User (Home Healthcare Settings, Hospitals & Clinics) – Global Industry Analysis and Demand Forecast to 2030

P&S Market Researchが発行した調査報告書(PS21NO023)◆商品コード:PS21NO023
◆発行会社(リサーチ会社):P&S Market Research
◆発行日:2021年11月
◆ページ数:n/a
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
5 UserUSD6,400 ⇒換算¥947,200見積依頼/購入/質問フォーム
Enterprise UserUSD8,400 ⇒換算¥1,243,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本市場調査資料では、良性前立腺肥大症(BPH)治療の世界市場を広く調査・分析し、調査背景、調査手法、エグゼクティブサマリー、産業専門家の意見/KOL、市場指標、種類別(薬物治療、手術治療)分析、エンドユーザー別(在宅医療、病院・クリニック)分析、産業動向、政策・規制状況、市場規模・予測、地域別分析、競争状況、企業情報など、以下の構成でまとめております。
・調査背景
・調査手法
・エグゼクティブサマリー
・産業専門家の意見/KOL
・市場指標
・良性前立腺肥大症(BPH)治療の世界市場規模:種類別(薬物治療、手術治療)
・良性前立腺肥大症(BPH)治療の世界市場規模:エンドユーザー別(在宅医療、病院・クリニック)
・産業動向
・政策・規制状況
・市場規模・予測
・良性前立腺肥大症(BPH)治療の世界市場規模:地域別
・競争状況
・企業情報

Market Overview
The global benign prostatic hyperplasia treatment market was valued around $10 billion in 2020, which is projected to grow with healthy growth rate during the forecast period (2021–2030). The major factors behind the growth of the market are the increasing aging population, rising awareness about prostate cancer and its treatment, growing technological advancements in personalized medicine, increasing adoption of minimally invasive procedures, and improving healthcare infrastructure across the world.

As a result of the COVID-19 epidemic, governments in several nations have taken strategic measures to protect citizens, such as lockdowns and social distancing. The economic crisis generated by the epidemic has had a negative impact on manufacturers across the globe, including those of BPH drugs and surgical devices. Furthermore, the availability of raw materials has been significantly affected due to the government limitations on internal and international trade to contain the spread of the virus. This further restrained the growth of the BPH treatment market by affecting the manufacturing of active pharmaceutical ingredients (APIs) due to the shortage of raw materials.

Due to Preference for Drugs for Management of Disorder, Drug Treatment Category Was Larger
The drug treatment category had the larger share in 2020, based on type. This was majorly due to the high adoption of medicines to manage and treat the disorder at the acute and sub-acute levels. In addition, medication is prescribed for post-operative treatment, which leads to their higher consumption compared to surgical devices.

Due to Rising Preference for Comfort during Pre- and Post-Operative Care, Home Healthcare Settings Category To Grow Fastest
The home healthcare settings category is expected to witness the fastest growth during the forecast period in the benign prostatic hyperplasia treatment market, based on end user. This is ascribed to the rising use of drugs and devices that are used for pre-surgical treatment. In addition, patients are also prescribed medication for a few weeks after being discharged from the hospital, which is majorly consumed at homes.

Owing to Rising Geriatric Population, North America Accounted for Largest Market Share
Geographically, North America generated the highest revenue in the benign prostatic hyperplasia treatment market in 2020. This is mainly attributed to the increasing geriatric population, which is highly susceptible to BPH and other lower urinary tract diseases. In addition, the rising number of innovations in BPH devices, increasing awareness about the condition, and enhanced reimbursement coverage continue to boost the volume of BHP treatments in the region.

Product Approvals and Launches Are Key Trend
Surgery is a better alternative to the management of BPH via medication, but patients have a higher preference for medication due to the post-operative damage to the body caused by surgical cuts and burns. The development of minimally invasive procedures has brought about a change in patients’ perception and given surgical device manufacturers a competitive edge. For instance, in August 2020, the UroLift enhanced tissue control system was developed by Teleflex Inc. to treat people with BPH. Small implants that retain the prostate lobes in a retracted position can be inserted into the system to open the urethra. The device is designed to treat patients with difficult a prostatic architecture, such as those who have big lateral lobes and an obstructive median lobe.

Increasing Geriatric Population Is Boosting Market Growth
According to the United Nations Department of Economic and Social Affairs (UNDESA) report on the global aging population, the number of people aged 65 and above is rapidly increasing, and it would more than double by 2050. The increase in research and development (R&D) activities to treat the prostate condition, especially in the senior population, which requires additional care, have enhanced BPH treatment devices, thus supporting the worldwide benign prostatic hyperplasia treatment market advanced.

❖ レポートの目次 ❖

Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Analysis Period
1.4 Market Data Reporting Unit
1.4.1 Value
1.5 Market Size Breakdown by Segment
1.5.1 Market Segmentation by Type
1.5.2 Market Segmentation by End User
1.5.3 Market Segmentation by Region
1.5.4 Market Segment Analysis of Countries
1.6 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.1.1 Paid
2.1.2 Unpaid
2.1.3 P&S Intelligence Database
2.2 Primary Research
2.2.1 Breakdown of Primary Research, by Region
2.2.2 Breakdown of Primary Research, by Industry Participant
2.2.3 Breakdown of Primary Research, by Designation
2.2.4 Breakdown of Primary Research, by Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
2.6 Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Voice of Industry Experts/KOLs
Chapter 5. Market Indicators
Chapter 6. Definition of Market Segments
6.1 By Type
6.1.1 Drug Treatment
6.1.1.1 Alpha blockers
6.1.1.1.1 Alfuzosin
6.1.1.1.2 Doxazosin
6.1.1.1.3 Tamsulosin
6.1.1.1.4 Silodosin
6.1.1.2 5-Alpha reductase inhibitors
6.1.1.2.1 Finasteride
6.1.1.2.2 Dutasteride
6.1.1.3 Others
6.1.2 Surgical Treatment
6.1.2.1 TURP
6.1.2.2 TUMT
6.1.2.3 TUNA
6.1.2.4 Laser therapy
6.1.2.5 Prostatic stenting
6.1.2.6 UroLift therapy
6.1.2.7 Rezûm therapy
6.1.2.8 Other surgeries
6.2 By End User
6.2.1 Home Healthcare Settings
6.2.2 Hospitals & Clinics
Chapter 7. Industry Outlook
7.1 Market Dynamics
7.1.1 Trends
7.1.2 Drivers
7.1.3 Impact Analysis of Drivers on Market Forecast
7.1.4 Restraints
7.1.5 Impact Analysis of Restraints on Market Forecast
7.2 Impact of COVID-19 on BPH Treatment Market
7.3 Porter’s Five Forces Analysis
7.3.1 Bargaining Power of Buyers
7.3.2 Bargaining Power of Suppliers
7.3.3 Intensity of Rivalry
7.3.4 Threat of New Entrants
7.3.5 Threat of Substitutes
Chapter 8. Policy and Regulatory Landscape
8.1 North America
8.2 Europe
8.3 APAC
8.4 LATAM
8.5 MEA
Chapter 9. Global Market Size and Forecast
9.1 Overview
9.2 Market Revenue, by Type (2015–2030)
9.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
9.2.1.1 Alpha blockers market revenue, by type (2015–2030)
9.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
9.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
9.3 Market Revenue, by End User (2015–2030)
9.4 Market Revenue, by Region (2015–2030)
Chapter 10. North America Market Size and Forecast
10.1 Overview
10.2 Market Revenue, by Type (2015–2030)
10.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
10.2.1.1 Alpha blockers market revenue, by type (2015–2030)
10.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
10.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
10.3 Market Revenue, by End User (2015–2030)
10.4 Market Revenue, by Country (2015–2030)
Chapter 11. Europe Market Size and Forecast
11.1 Overview
11.2 Market Revenue, by Type (2015–2030)
11.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
11.2.1.1 Alpha blockers market revenue, by type (2015–2030)
11.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
11.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
11.3 Market Revenue, by End User (2015–2030)
11.4 Market Revenue, by Country (2015–2030)
Chapter 12. APAC Market Size and Forecast
12.1 Overview
12.2 Market Revenue, by Type (2015–2030)
12.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
12.2.1.1 Alpha blockers market revenue, by type (2015–2030)
12.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
12.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
12.3 Market Revenue, by End User (2015–2030)
12.4 Market Revenue, by Country (2015–2030)
Chapter 13. LATAM Market Size and Forecast
13.1 Overview
13.2 Market Revenue, by Type (2015–2030)
13.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
13.2.1.1 Alpha blockers market revenue, by type (2015–2030)
13.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
13.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
13.3 Market Revenue, by End User (2015–2030)
13.4 Market Revenue, by Country (2015–2030)
Chapter 14. MEA Market Size and Forecast
14.1 Overview
14.2 Market Revenue, by Type (2015–2030)
14.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
14.2.1.1 Alpha blockers market revenue, by type (2015–2030)
14.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
14.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
14.3 Market Revenue, by End User (2015–2030)
14.4 Market Revenue, by Country (2015–2030)
Chapter 15. U.S. Market Size and Forecast
15.1 Overview
15.2 Market Revenue, by Type (2015–2030)
15.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
15.2.1.1 Alpha blockers market revenue, by type (2015–2030)
15.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
15.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
15.3 Market Revenue, by End User (2015–2030)
Chapter 16. Canada Market Size and Forecast
16.1 Overview
16.2 Market Revenue, by Type (2015–2030)
16.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
16.2.1.1 Alpha blockers market revenue, by type (2015–2030)
16.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
16.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
16.3 Market Revenue, by End User (2015–2030)
Chapter 17. Germany Market Size and Forecast
17.1 Overview
17.2 Market Revenue, by Type (2015–2030)
17.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
17.2.1.1 Alpha blockers market revenue, by type (2015–2030)
17.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
17.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
17.3 Market Revenue, by End User (2015–2030)
Chapter 18. France Market Size and Forecast
18.1 Overview
18.2 Market Revenue, by Type (2015–2030)
18.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
18.2.1.1 Alpha blockers market revenue, by type (2015–2030)
18.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
18.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
18.3 Market Revenue, by End User (2015–2030)
Chapter 19. U.K. Market Size and Forecast
19.1 Overview
19.2 Market Revenue, by Type (2015–2030)
19.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
19.2.1.1 Alpha blockers market revenue, by type (2015–2030)
19.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
19.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
19.3 Market Revenue, by End User (2015–2030)
Chapter 20. Italy Market Size and Forecast
20.1 Overview
20.2 Market Revenue, by Type (2015–2030)
20.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
20.2.1.1 Alpha blockers market revenue, by type (2015–2030)
20.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
20.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
20.3 Market Revenue, by End User (2015–2030)
Chapter 21. Spain Market Size and Forecast
21.1 Overview
21.2 Market Revenue, by Type (2015–2030)
21.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
21.2.1.1 Alpha blockers market revenue, by type (2015–2030)
21.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
21.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
21.3 Market Revenue, by End User (2015–2030)
Chapter 22. China Market Size and Forecast
22.1 Overview
22.2 Market Revenue, by Type (2015–2030)
22.2.1 Drug Treatment Market Revenue, by Type (2215–2230)
22.2.1.1 Alpha blockers market revenue, by type (2015–2030)
22.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
22.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
22.3 Market Revenue, by End User (2015–2030)
Chapter 23. Japan Market Size and Forecast
23.1 Overview
23.2 Market Revenue, by Type (2015–2030)
23.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
23.2.1.1 Alpha blockers market revenue, by type (2015–2030)
23.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
23.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
23.3 Market Revenue, by End User (2015–2030)
Chapter 24. India Market Size and Forecast
24.1 Overview
24.2 Market Revenue, by Type (2015–2030)
24.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
24.2.1.1 Alpha blockers market revenue, by type (2015–2030)
24.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
24.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
24.3 Market Revenue, by End User (2015–2030)
Chapter 25. Australia Market Size and Forecast
25.1 Overview
25.2 Market Revenue, by Type (2015–2030)
25.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
25.2.1.1 Alpha blockers market revenue, by type (2015–2030)
25.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
25.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
25.3 Market Revenue, by End User (2015–2030)
Chapter 26. South Korea Market Size and Forecast
26.1 Overview
26.2 Market Revenue, by Type (2015–2030)
26.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
26.2.1.1 Alpha blockers market revenue, by type (2015–2030)
26.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
26.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
26.3 Market Revenue, by End User (2015–2030)
Chapter 27. Brazil Market Size and Forecast
27.1 Overview
27.2 Market Revenue, by Type (2015–2030)
27.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
27.2.1.1 Alpha blockers market revenue, by type (2015–2030)
27.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
27.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
27.3 Market Revenue, by End User (2015–2030)
Chapter 28. Mexico Market Size and Forecast
28.1 Overview
28.2 Market Revenue, by Type (2015–2030)
28.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
28.2.1.1 Alpha blockers market revenue, by type (2015–2030)
28.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
28.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
28.3 Market Revenue, by End User (2015–2030)
Chapter 29. Saudi Arabia Market Size and Forecast
29.1 Overview
29.2 Market Revenue, by Type (2015–2030)
29.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
29.2.1.1 Alpha blockers market revenue, by type (2015–2030)
29.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
29.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
29.3 Market Revenue, by End User (2015–2030)
Chapter 30. South Africa Market Size and Forecast
30.1 Overview
30.2 Market Revenue, by Type (2015–2030)
30.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
30.2.1.1 Alpha blockers market revenue, by type (2015–2030)
30.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
30.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
30.3 Market Revenue, by End User (2015–2030)
Chapter 31. Competitive Landscape
31.1 List of Market Players and Their Offerings
31.2 Market Share Analysis of Key Players
31.2.1 Global
31.2.2 North America
31.3 Competitive Analysis of Key Players
31.4 Product Comparison of Key Players
31.5 Recent Strategic Developments by Key Players
Chapter 32. Company Profiles
32.1 Pfizer Inc.
32.1.1 Business Overview
32.1.2 Product and Service Offerings
32.1.3 Key Financial Summary
32.2 Company 2
32.2.1 Business Overview
32.2.2 Product and Service Offerings
32.2.3 Key Financial Summary
32.3 Company 3
32.3.1 Business Overview
32.3.2 Product and Service Offerings
32.3.3 Key Financial Summary
32.4 Company 4
32.4.1 Business Overview
32.4.2 Product and Service Offerings
32.4.3 Key Financial Summary
32.5 Company 5
32.5.1 Business Overview
32.5.2 Product and Service Offerings
32.5.3 Key Financial Summary
32.6 Company 6
32.6.1 Business Overview
32.6.2 Product and Service Offerings
32.6.3 Key Financial Summary
32.7 Company 7
32.7.1 Business Overview
32.7.2 Product and Service Offerings
32.7.3 Key Financial Summary
32.8 Company 8
32.8.1 Business Overview
32.8.2 Product and Service Offerings
32.8.3 Key Financial Summary
32.9 Company 9
32.9.1 Business Overview
32.9.2 Product and Service Offerings
32.9.3 Key Financial Summary
32.10 Company 10
32.10.1 Business Overview
32.10.2 Product and Service Offerings
32.10.3 Key Financial Summary
Chapter 33. Appendix
33.1 Abbreviations
33.2 Sources and References
33.3 Related Reports



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の良性前立腺肥大症(BPH)治療市場:産業分析・成長予測(~2030)(Benign Prostatic Hyperplasia Treatment Market Research Report: By Type (Drug Treatment, Surgical Treatment), End User (Home Healthcare Settings, Hospitals & Clinics) – Global Industry Analysis and Demand Forecast to 2030)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆